Miwa, Kunihisa · eNeurologicalSci · 2025 · DOI
This small study looked at whether a common antibiotic called minocycline might help people with ME/CFS, including those with long COVID. Fifty-five patients took minocycline for about 6 weeks, and 80% of those who completed the treatment reported meaningful improvements in their symptoms like fatigue, brain fog, and sleep problems. The treatment worked best for people early in their illness (within 6 months of symptom onset).
This is one of the first studies examining minocycline for ME/CFS treatment, and it shows promising results particularly for early-stage disease and long COVID—conditions with limited evidence-based therapeutic options. Understanding whether early antibiotic intervention might help ME/CFS patients could significantly change clinical management approaches during the critical early disease period.
This observational study cannot prove minocycline causes symptom improvement due to lack of a control group, placebo effect cannot be excluded, and the small sample size and short follow-up period limit generalizability. The study does not establish optimal dosing, long-term safety, mechanism of action, or whether benefits persist after treatment ends.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.